

**Rabbit Anti-EGFR (E746-A750del Specific) [SP111]: RM0444, RM0444RTU7**

**Intended Use:** For Research Use Only

**Description:** Two types of mutations account for approximately 90% of mutated cases: a specific point mutation, L858R, which occurs in exon 21 and short in-frame deletions in exon 19. A common lesion in exon 19 is the deletion of E746-A750, although other variants occur. IHC-based EGFR E746-A750del specific antibody is designed to detect deletion of E746-A750 in exon 19. Deletion in exon 19 is associated with response of non-small cell lung carcinoma (NSCLC) to gefitinib or erlotinib monotherapy.

**Specifications:**


Clone: SP111  
 Source: Rabbit  
 Isotype: IgG  
 Reactivity: Human  
 Immunogen: Synthetic peptide corresponding to E746-A750 del mutant sequence of human EGFR  
 Localization: Membrane  
 Formulation: Antibody in PBS pH7.4, containing BSA and  $\leq 0.09\%$  sodium azide (NaN<sub>3</sub>)  
 Storage: Store at 2°- 8°C.  
 Applications: IHC, Flow Cyt., ICC/IF, WB  
 Package:

Description	Catalog No.	Size
EGFR (E746-A750del Specific) Concentrated	RM0444	1 ml
EGFR (E746-A750del Specific) Prediluted	RM0444RTU7	7 ml

**IHC Procedure\*:**

Positive Control Tissue: Lung carcinoma E746-A750 del specific  
 Concentrated Dilution: 25-100  
 Pretreatment: Citrate PH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C  
 Incubation Time and Temp: 30-60 minutes @ RT  
 Detection: Refer to the detection system manual

\* Result should be confirmed by an established diagnostic procedure.



FFPE human lung carcinoma stained with anti-EGFR (E746-A750del specific) using DAB

**References:**

1. Complex mutations subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. Marchetti, A., et al. PLoS ONE on 31 July 2012.
2. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. Huang, W. C., Chen, Y. J., et al. Journal of Biological Chemistry on 10 June 2011.
3. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. Kato, Y., et al. Journal of Thoracic Oncology, 1 October 2010.

Doc. 100-RM0444  
Rev. A